

PRODUCT DATA SHEET

Bioworld Technology CO., Ltd.



Cytokeratin 14/16 (S5) Peptide

Cat No.: BS1200P

Background

In Bowen's disease, the characteristic malignancy of the epidermis exhibits distinct expression patterns of Cytokeratin 14. Mutations in the gene encoding human Cytokeratin 14 lead to epidermolysis bullosa simplex, an inherited skin disorder characterized by skin blistering due to basal keratinocyte fragility. Cytokeratin 16 is expressed in benign stratified squamous epithelium and squamous cell carcinoma of the head and neck, as well as luminal cells of mammary gland and sweat ducts. It is absent in noninvasive breast carcinomas and normal breast tissue. Mutations in the Cytokeratin 16 gene cause various diseases, including pachyonychia congenita type 1 (PC1), nonepidermolytic palmoplantar keratoderma (NEPPK) and unilateral palmoplantar verrucous nevus (UPVN).

Swiss-Prot

P02533/P08779

Applications

Blocking

Specificity

This peptide can be used with studies using BS1200 Cytokeratin 14/16 (S5) pAb.

Purification & Purity

Synthetic peptide Cytokeratin 14/16 (S5). (Note: the amino acid sequence is proprietary). The purity is > 98%.

Product

1 mg/ml in DI water.

Storage & Stability

Store at 4 °C short term. Aliquot and store at -20 °C long term. Avoid freeze-thaw cycles.

Research Use

For research use only, not for use in diagnostic procedure.